MiNK Therapeutics Inc (INKT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$10.05-5.19%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · INKT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
INKT — earnings miss
Dated 2026-08-13
and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
Why it matters: More open sites could help the trial enroll patients beyond its first Ukraine site.
Supportive ifMiNK names at least one U.S. site as open and enrolling patients in C-1300-02.
Worry ifMiNK reports that U.S. site opening is delayed, or names no U.S. site as open by its next update.
Why it matters: MiNK had $8.8 million in cash at June 30, 2026. A sharp drop could limit room to fund its trials.
Worry ifThe November 13, 2026 results show cash and cash equivalents below $5 million.
Less concerning ifThe November 13, 2026 results show cash and cash equivalents at or above $5 million.
Why it matters: MiNK has limited cash and is advancing several programs. New outside funding could help support that work without new share sales.
Supportive ifMiNK announces a new grant or partnership with a stated dollar amount. The funds support clinical or development work.
Worry ifMiNK reports no new outside funding and raises cash through share sales to fund its programs.
Why it matters: The first patient notes are early and uncontrolled. A randomized study can test if agenT-797 helps patients recover.
Watch forIn the next data update, more patients in the agenT-797 group survive or have days free from a ventilator than in the placebo group. No major safety issue appears.
Also watch forThe agenT-797 group has no better survival or days free from a ventilator than the placebo group. Or, it shows a major safety issue.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$231 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $651 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,786 loss on $10,000 · 37.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The program is new and needs case-by-case approval. Paid requests could show that it brings in money and can run across borders.
Supportive ifMiNK reports revenue from at least one approved, paid Brazil patient request.
Worry ifMiNK reports no paid requests or receipts by its next update, or says Brazil access has stopped.